IL195087A - Water-free lactate salts of N - hydroxy – 3– [4 - [[[2– (2 – methyl – 1H– indole – 3 – il) ethyl] amino] methyl] phenyl] –2 E – 2– propanamide and medicinal preparations containing them - Google Patents

Water-free lactate salts of N - hydroxy – 3– [4 - [[[2– (2 – methyl – 1H– indole – 3 – il) ethyl] amino] methyl] phenyl] –2 E – 2– propanamide and medicinal preparations containing them

Info

Publication number
IL195087A
IL195087A IL195087A IL19508708A IL195087A IL 195087 A IL195087 A IL 195087A IL 195087 A IL195087 A IL 195087A IL 19508708 A IL19508708 A IL 19508708A IL 195087 A IL195087 A IL 195087A
Authority
IL
Israel
Prior art keywords
salt
methyl
hydroxy
phenyl
propenamide
Prior art date
Application number
IL195087A
Other languages
English (en)
Hebrew (he)
Other versions
IL195087A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL195087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL195087A0 publication Critical patent/IL195087A0/en
Publication of IL195087A publication Critical patent/IL195087A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL195087A 2006-06-12 2008-11-03 Water-free lactate salts of N - hydroxy – 3– [4 - [[[2– (2 – methyl – 1H– indole – 3 – il) ethyl] amino] methyl] phenyl] –2 E – 2– propanamide and medicinal preparations containing them IL195087A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14
PCT/US2007/070558 WO2007146715A1 (fr) 2006-06-12 2007-06-07 Sels de n-hydroxy-3-[4-[[[2-(2-méthyl-1h-indol-3-yl)éthyl]amino]méthyl]phényl]-2e-2-propénamide

Publications (2)

Publication Number Publication Date
IL195087A0 IL195087A0 (en) 2009-08-03
IL195087A true IL195087A (en) 2012-10-31

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195087A IL195087A (en) 2006-06-12 2008-11-03 Water-free lactate salts of N - hydroxy – 3– [4 - [[[2– (2 – methyl – 1H– indole – 3 – il) ethyl] amino] methyl] phenyl] –2 E – 2– propanamide and medicinal preparations containing them

Country Status (38)

Country Link
US (3) US20090197936A1 (fr)
EP (1) EP2032531B1 (fr)
JP (2) JP2009540005A (fr)
KR (2) KR101629352B1 (fr)
AR (1) AR061298A1 (fr)
AU (1) AU2007257962B2 (fr)
BR (1) BRPI0712771A2 (fr)
CA (1) CA2654439C (fr)
CL (1) CL2007001692A1 (fr)
CR (1) CR10439A (fr)
DK (1) DK2032531T3 (fr)
EA (1) EA015212B1 (fr)
EC (1) ECSP088979A (fr)
ES (1) ES2570934T3 (fr)
GE (1) GEP20105125B (fr)
GT (1) GT200800279A (fr)
HK (1) HK1126496A1 (fr)
HN (1) HN2008001859A (fr)
HR (1) HRP20160291T1 (fr)
HU (1) HUE027126T2 (fr)
IL (1) IL195087A (fr)
JO (1) JO3138B1 (fr)
MA (1) MA30563B1 (fr)
ME (1) ME00531B (fr)
MX (1) MX2008015901A (fr)
MY (1) MY147345A (fr)
NO (1) NO341871B1 (fr)
NZ (1) NZ572547A (fr)
PE (1) PE20080937A1 (fr)
PL (1) PL2032531T3 (fr)
RS (1) RS54640B1 (fr)
SI (1) SI2032531T1 (fr)
SM (1) SMP200900002B (fr)
SV (1) SV2008003126A (fr)
TN (1) TNSN08501A1 (fr)
TW (1) TWI409254B (fr)
UY (1) UY30403A1 (fr)
WO (1) WO2007146715A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989494B2 (en) 2006-06-12 2011-08-02 Novartis Ag Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
WO2008086330A2 (fr) * 2007-01-10 2008-07-17 Novartis Ag Formulations d'inhibiteurs de la déacétylase
US8003700B2 (en) 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (fr) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Nouveaux sels et formes polymorphes de panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
US7989494B2 (en) * 2006-06-12 2011-08-02 Novartis Ag Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
US20090197936A1 (en) 2009-08-06
ECSP088979A (es) 2009-01-30
HUE027126T2 (en) 2016-08-29
KR101629352B1 (ko) 2016-06-13
BRPI0712771A2 (pt) 2012-09-25
ME00531B (fr) 2011-10-10
CL2007001692A1 (es) 2008-05-09
US20110112308A1 (en) 2011-05-12
JO3138B1 (ar) 2017-09-20
HN2008001859A (es) 2011-07-19
IL195087A0 (en) 2009-08-03
UY30403A1 (es) 2008-01-31
MY147345A (en) 2012-11-30
AU2007257962B2 (en) 2011-06-23
NO20090128L (no) 2009-03-11
CA2654439C (fr) 2014-08-05
AR061298A1 (es) 2008-08-20
KR20090026281A (ko) 2009-03-12
EP2032531A1 (fr) 2009-03-11
US20100286409A1 (en) 2010-11-11
EA200802382A1 (ru) 2009-06-30
RS54640B1 (en) 2016-08-31
PE20080937A1 (es) 2008-08-29
TWI409254B (zh) 2013-09-21
PL2032531T3 (pl) 2016-07-29
DK2032531T3 (en) 2016-04-11
EP2032531B1 (fr) 2016-02-10
GEP20105125B (en) 2010-11-25
HRP20160291T1 (hr) 2016-04-22
JP5771257B2 (ja) 2015-08-26
WO2007146715A1 (fr) 2007-12-21
AU2007257962A1 (en) 2007-12-21
NZ572547A (en) 2011-06-30
MX2008015901A (es) 2009-01-12
SV2008003126A (es) 2011-07-05
TW200815343A (en) 2008-04-01
SMAP200900002A (it) 2009-01-14
KR20150029765A (ko) 2015-03-18
CA2654439A1 (fr) 2007-12-21
EA015212B1 (ru) 2011-06-30
TNSN08501A1 (en) 2010-04-14
JP2009540005A (ja) 2009-11-19
GT200800279A (es) 2010-06-16
HK1126496A1 (zh) 2009-09-04
SI2032531T1 (sl) 2016-05-31
MA30563B1 (fr) 2009-07-01
CR10439A (es) 2009-01-15
NO341871B1 (no) 2018-02-12
SMP200900002B (it) 2010-01-19
JP2013256542A (ja) 2013-12-26
ES2570934T3 (es) 2016-05-23

Similar Documents

Publication Publication Date Title
IL195087A (en) Water-free lactate salts of N - hydroxy – 3– [4 - [[[2– (2 – methyl – 1H– indole – 3 – il) ethyl] amino] methyl] phenyl] –2 E – 2– propanamide and medicinal preparations containing them
AU2007257881B2 (en) Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
CA2654230C (fr) Procede de production d'un lactate de n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-acrylamide